Gender differences in the effects of angiotensin receptor blockers on cardiovascular disease

Current Pharmaceutical Design

Volumn 17, Issue 11, 2011, Pages 1090-1094

  Yoshida, Hiroshi ^a,b   Rosano, Giuseppe ^c   Shimizu, Mitsuyuki ^b   Mochizuki, Seibu ^b,d   Yoshimura, Michihiro ^b  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c IRCCS SAN RAFFAELE PISANA   (Italy)

^d MUSASHINO UNIVERSITY   (Japan)

Author keywords

Angiotensin receptor blocker (ARB); Blood pressure lowering; Cardiovascular disease; Gender; Large scaledrandomized study; Renin angiotensin aldosteron (RAA) system; Sex difference

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; PLACEBO; THIAZIDE DIURETIC AGENT; VALSARTAN;

ACUTE CORONARY SYNDROME; ANGINA PECTORIS; BLOOD PRESSURE REGULATION; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG EFFICACY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SEX DIFFERENCE; TREATMENT OUTCOME;

EID: 79958188560     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211795656909     Document Type: Review

References (35)

1. Whitworth JA, World Health Organization, International Society ofHypertension Writing Group. 2003 World Health Organization(WHO)/ International Society of Hypertension (ISH) statement onmanagement of hypertension. J Hypertens 2003; 21: 1983-92.
2. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalenceand blood pressure levels in 6 European countries, Canada,and the United States. JAMA 2003; 289: 2363-9.
3. Yusuf S, Hawken S, Ounpuu S, et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associatedwith myocardial infarction in 52 countries (the INTERHEARTstudy): case-control study. Lancet 2004; 364: 937-52.
4. Sytkowski PA, D'Agostino RB, Belanger A, Kannel WB. Sex andtime trends in cardiovascular disease incidence and mortality: theFramingham Heart Study, 1950-1989. Am J Epidemiol 1996; 143:338-50.
5. Shaw LJ, Bairey Merz CN, Pepine CJ, et al. WISE Investigators. Insights from the NHLBI-Sponsored Women's Ischemia SyndromeEvaluation (WISE) Study. Part I: gender differences in traditionaland novel risk factors, symptom evaluation, and gender-optimizeddiagnostic strategies. J Am Coll Cardiol 2006; 47 (Suppl 3): S4-S20.
6. Turnbull F, Woodward M, Anna V. Effectiveness of blood pressurelowering: evidence based comparisons between men and women. Expert Rev Cardiovasc Ther 2010; 8: 199-209.
7. Turnbull F, Woodward M, Neal B, et al. Do men and women responddifferently to blood pressure-lowering treatment? Results ofprospectively designed overviews of randomized trials. Eur Heart J 2008; 29: 2669-80.
8. Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults acrossthe age spectrum: current outcomes and control in the community. JAMA 2005; 294: 466-72.
9. Kim C, Redberg RF, Pavlic T, Eagle KA. A systematic review ofgender differences in mortality after coronary artery bypass graftsurgery and percutaneous coronary interventions. Clin Cardiol 2007; 30: 491-5.
10. Lip GY, Butt M. Gender and the response to blood pressureloweringtreatment. Eur Heart J 2008; 29: 2585-6.
11. Zanchetti A, Facchetti R, Cesana GC, Modena MG, Pirrelli A, Sega R. SIMONA participants. Menopause-related blood pressureincrease and its relationship to age and body mass index: the SIMONAepidemiological study. J Hypertens. (2005) 23: 2269-76.
12. Lee LV, Foody JM. Cardiovascular disease in women. Curr AtherosclerReport 2008; 10: 295-302.
13. Schulman IH, Aranda P, Raij L, Veronesi M, Aranda FJ, Martin R. Surgical menopause increases salt sensitivity of blood pressure. Hypertension 2006; 47: 1168-74.
14. Rockelhoff JE. Gender difference s in the regulation of blood pressures. Hypertension 2001; 37: 1199-208.
15. Izumi Y, Matsumoto K, Ozawa Y, et al. Effect of age at menopauseon blood pressure in postmenopausal women. Am J Hypertens 2007; 20: 1045-50.
16. McGuire BB, Watson RW, Pérez-Barriocanal F, Fitzpatrick JM, Docherty NG. Gender differences in the renin-angiotensin and nitricoxide systems: relevance in the normal and diseased kidney. Kidney Blood Press Res 2007; 30: 67-80.
17. Harrison-Bernard LM, Schulman IH, Raij L. Postovariectomyhypertension is linked to increased renal AT1 receptor and salt sensitivity. Hypertension 2003; 42: 1157-63.
18. Dubey RK, Oparil S, Imthurn B, Jackson EK. Sex hormones andhypertension. Cardiovac Res 2002; 53: 688-708.
19. Coylewright M, Reckelhoff JF, Ouyang P. Menopause and hypertension:An age-old debate. Hypertension 2008; 51: 952-9.
20. Gueyffier F, Boutitie F, Boissel JP. Effect of antihypertensive drugtreatment on cardiovascular outcomes in women and men. A metaanalysisof individual patient data from randomized, controlled trials. The INDANA Investigators. Ann Intern Med 1997; 126: 761-7.
21. Frazier CG, Shah SH, Armstrong PW, et al. SYMPHONY and theSecond SYMPHONY Investigators. Prevalence and managementof hypertension in acute coronary syndrome patients varies by sex:observations from the Sibrafiban versus aspirin to Yield MaximumProtection from ischemic Heart events postacute cOro Nary sYndromes(SYMPHONY) randomized clinical trials. Am Heart J 2005; 150: 1260-7.
22. Dahlöf B, Devereux RB, Kjeldsen SE, et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan InterventionFor Endpoint reduction in hypertension study (LIFE): a randomisedtrial against atenolol. Lancet 2002; 359: 995-1003.
23. Os I, Franco V, Kjeldsen SE, et al. Effects of losartan in womenwith hypertension and left ventricular hypertrophy: results from theLosartan Intervention for Endpoint Reduction in HypertensionStudy. Hypertension 2008; 51: 1103-8.
24. Lithell H, Hansson L, Skoog I, et al. SCOPE Study Group. TheStudy on Cognition and Prognosis in the Elderly (SCOPE): principalresults of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875-86.
25. Trenkwalder P, Elmfeldt D, Hofman A, et al. Study on COgnitionand Prognosis in the Elderly (SCOPE). The Study on COgnitionand Prognosis in the Elderly (SCOPE) - major CV events andstroke in subgroups of patients. Blood Press 2005; 14: 31-7.
26. Julius S, Kjeldsen SE, Weber M, et al. VALUE trial group. Outcomesin hypertensive patients at high cardiovascular risk treatedwith regimens based on valsartan or amlodipine: the VALUE randomisedtrial. Lancet 2004; 363: 2022-31.
27. Zanchetti A, Julius S, Kjeldsen S, et al. Outcomes in subgroups ofhypertensive patients treated with regimens based on valsartan andamlodipine: An analysis of findings from the VALUE trial. J Hypertens 2006; 24: 2163-8.
28. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. Arandomized trial of the angiotensin-receptor blocker valsartan inchronic heart failure. N Engl J Med 2001; 345: 1667-75.
29. Majahalme SK, Baruch L, Aknay N, et al. Val-HeFT Study Investigators. Comparison of treatment benefit and outcome in womenversus men with chronic heart failure (from the Valsartan HeartFailure Trial). Am J Cardiol 2005; 95: 529-32.
30. Mochizuki S, Dahlöf B, Shimizu M, et al. Jikei Heart Study group. Valsartan in a Japanese population with hypertension and othercardiovascular disease (Jikei Heart Study): a randomised, openlabel,blinded endpoint morbidity-mortality study. Lancet 2007;369: 1431-9.
31. Yoshida H, Shimizu M, Ikewaki K, et al. Jikei Heart Study group. Sex differences in effects of valsartan administration on cardiovascularoutcomes in hypertensive patients: findings from the JikeiHeart Study. J Hypertens 2010; 28: 1150-7.
32. Sawada T, Yamada H, Dahlöf B, Matsubara H. Effects of valsartanon morbidity and mortality in uncontrolled hypertensive patientswith high cardiovascular risk: Kyoto Heart Study. Eur Heart J 2009; 30: 2461-9.
33. Chapman AB, Schwartz GL, Boerwinkle E, Turner ST. Predictorsof antihypertensive response to a standard dose of hydrochlorothiazidefor essential hypertension. Kidney Int 2002; 61: 1047-55.
34. Kawano H, Soejima H, Kojima S, Kitagawa A, Ogawa H. JapaneseAcute Coronary Syndrome Study (JACSS) Investigators. Sex differencesof risk factors for acute myocardial infarction in Japanesepatients. Circ J 2006; 70: 513-7.
35. NIPPON DATA80 Research Group. Risk assessment chart fordeath from cardiovascular disease based on a 19-year follow-upstudy of a Japanese representative population. Circ J 2006; 70:1249-55.